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Abstract The purpose of this study was to evaluate, in
vitro and in vivo, doxorubicin-loaded poly (vinyl alcohol-
sodium acrylate) copolymer microspheres [QuadraSphere
microspheres (QSMs)] for transcatheter arterial delivery in
an animal model of liver cancer. Doxorubicin loading
efficiency and release profile were first tested in vitro. In
vivo, 15 rabbits, implanted with a Vx-2 tumor in the liver,
were divided into three groups of five rabbits each, based
on the time of euthanasia. Twenty-five milligrams of QSMs
was diluted in 10 ml of a 10 mg/ml doxorubicin solution
and 10 ml of nonionic contrast medium for a total volume
of 20 ml. One milliliter of a drug-loaded QSM solution
containing 5 mg of doxorubicin was injected into the tumor
feeding artery. Plasma doxorubicin and doxorubicinol
concentrations, and intratumoral and peritumoral doxoru-
bicin tissue concentrations, were measured. Tumor speci-
mens were pathologically evaluated to record tumor
necrosis. As a control, one animal was blandly embolized
with plain QSMs in each group. In vitro testing of QSM
doxorubicin loadability and release over time showed 82–
94% doxorubicin loadability within 2 h and 6% release
within the first 6 h after loading, followed by a slow release
pattern. In vivo, the doxorubicin plasma concentration
declined at 40 min. The peak doxorubicin intratumoral
concentration was observed at 3 days and remained
detectable till the study’s end point (7 days). Mean per-
centage tumor cell death in the doxorubicin QSM group
was 90% at 7 days and 60% in the bland QSM emboliza-
tion group. In conclusion, QSMs can be efficiently loaded
with doxorubicin. Initial experiments with doxorubicin-
loaded QSMs show a safe pharmacokinetic profile and
effective tumor killing in an animal model of liver cancer.
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Introduction
Recently, microspheres loaded with chemotherapeutic
agents, such as doxorubicin and irinotecan, have been
introduced into clinical practice for transcatheter delivery
and palliative treatment of liver cancer. These micro-
spheres contain anionic groups which may interact with
positively charged groups of doxorubicin or irinotecan by
an ion-exchange mechanism, leading to controlled and
sustained intratumoral drug deposition, as well as
K.-H. Lee  E. A. Liapi  M. Buijs  J. A. Vossen 
V. P. Ventura  J.-F. H. Geschwind
Division of Vascular and Interventional Radiology, The Russell
H. Morgan Department of Radiology, The Johns Hopkins
University School of Medicine, 600 North Wolfe Street,
Baltimore, MD 21287, USA
K.-H. Lee
Division of Interventional Radiology, Department of Radiology
& Research Institute of Radiological Science, Severance
Hospital, Yonsei University College of Medicine, Seoul,
Republic of Korea
C. Cornell
BioSphere Medical, Rockland, MA 02370, USA
P. Reb
Research and Development Department, Biosphere Medical,
Roissy Charles de Gaulle, France
J.-F. H. Geschwind (&)
Division of Vascular and Interventional Radiology, The Johns
Hopkins Hospital, 600 North Wolfe Street, Blalock 545,
Baltimore, MD 21287, USA
e-mail: jfg@jhmi.edu
123
Cardiovasc Intervent Radiol (2010) 33:576–582
DOI 10.1007/s00270-010-9794-1
decreased systemic toxicity [1–5]. There is preliminary
preclinical and clinical evidence that drug-loaded micro-
spheres are a highly efficient method for drug delivery, as
shown by the high intratumoral concentrations and low
doxorubicin plasma levels [3].
Poly(vinyl alcohol-sodium acrylate) copolymer micro-
spheres [QuadraSpheres microspheres (QSMs); BioSphere
Medical, Inc., Rockland, MA, USA] are one type of
commercially available spherical and calibrated micro-
spheres. Hori and his colleagues first reported the suc-
cessful utilization of these polycopolymer microspheres
composed of vinyl alcohol and sodium acrylate in 1996 [6].
Hepaspheremicrospheres are identical in all respects to
QSMs and are marketed in the European Union and Japan.
Translational and clinical studies have reported their
application for embolization of hepatic tumors and vascular
malformations in Europe and Japan [7–10]. Preliminary
clinical studies in Europe have shown evidence that these
microspheres can be successfully loaded with doxorubicin,
epirubicin, or oxaliplatin. However, the pharmacokinetic
profile of drug-loaded QSMs has never been prospectively
tested in a preclinical setting.
In this study, our aim was to evaluate, in vitro and in
vivo, the pharmacokinetic profile of doxorubicin-loaded
QSMs as well as their tumoricidal effect when delivered
intra-arterially into the Vx-2 liver tumor model in rabbit.
Materials and Methods
Biophysical and Biochemical Properties
of QuadraSphere Microspheres
Most of the basic biological and biophysical properties of
QSMs, such as biocompatibility, hydrophilia, and nonre-
sorbability, have been demonstrated to be similar to these
of other commercially available micropsheres. However,
QSMs possess the unique feature of expanding in size
when exposed to an aqueous solution, with predictable and
homogeneous size ranges. Once the dry form of poly(vinyl
alcohol-sodium acrylate) copolymer microspheres is
exposed to aqueous solution (0.9% NaCl, blood, and non-
ionic contrast medium), it swells to about four times the
size of its diameter and 64 times its volume within 10 min
(Fig. 1). The diameter of the swollen form is quite
invariable and predictably proportional to its dry form size.
For instance, 50–100 lm in dry form may expand up to
200–400 lm, 100–150 lm may expand to 400–600 lm,
and 150–200 lm may expand to 600–800 lm when
hydrated. A 50- to 100-lm-sized dry form was used in this
study, resulting in 200- to 400-lm sized hydrated micro-
spheres. The hydrated microspheres are compressible and
this results in good transcatheter injectability as well as
intravascular distribution according to the shape of vascu-
lature [10].
Another feature of QSM is that their negatively charged
acrylate groups of QSMs may interact with the positively
charged protonated amine group of the doxorubicin hydro-
chloride, leading to a microscopic change of color (Fig. 2).
In Vitro Drug Loadability and Controlled Release
Doxorubicin [Yick-Vic Chemicals & Pharmaceuticals (HK)
Ltd.] was provided in dry form and prepared by solubilizing
the drug with 0.9% NaC in a total of 10 ml. Twenty-five
milligrams (±2 mg) of dry QSMs was weighted and
introduced into a 10-ml vial containing 100 mg of doxo-
rubicin. The solution was then gently agitated and let to
reconstitute for at least 10 min. In vitro measurement of the
doxorubicin concentration in the supernatant solution was
performed by drawing 150 ll of a solution containing
microspheres in a solution. The concentration of doxoru-
bicin was analyzed by reverse-phase high-performance
Fig. 1 Dry form of QuadraSphere microspheres
Fig. 2 Microscopic images of doxorubicin-loaded hydrated Quadra-
Sphere microspheres. Note that the microspheres acquire a red color
after doxorubicin loading (photographic evidence of doxorubicin
loading) as well as increase in diameter (swell after hydration;
compare with Fig. 1) (Color figure online)
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liquid chromatography (Uptisphere C18 column; 150 9
4.6 mm). The elution phase consisted inof 30% (v/v) ace-
tonitrile and 0.1% (v/v) trifluoroacetic acid in water. UV
detection was at kmax 480 nm. The loading efficiency was
calculated using the following rule:
The Bio-Rad apparatus was then used as a means of
simulating the in vivo blood flow to evaluate the release of
doxorubicin from the QSMs. The microspheres were then
weighed and placed in a column to which 10 ml of the
doxorubicin solution was added. They were let reconstitute
for 10 min. The solution flow rate was 2 ml/min. The
doxorubicin concentration over time was analyzed with
high-performance liquid chromatography by extracting
500 ll from the solution reservoir at each time point. The
mean diameters of the three tested size ranges were 90,
121, and 170 lm.
In Vitro Doxorubicin Loading into QuadraSphere
Microspheres
One hundred milligrams of doxorubicin powder was sol-
ubilized in 10 ml of nonionic contrast medium (Visipaque
270; Iodixanol, Nicomed Inc., Princeton, NJ). Twenty-five
milligrams of QSMs was added to the solution and the
mixture let reconstitute for 2 h. The solution was then
aspirated in a 30-ml syringe, where another 10 ml of the
same contrast medim was added to a total volume of 20 ml.
Finally, 1 ml of the above solution containing QSMs in a
5 mg/ml concentration of doxorubicin was injected into the
tumor feeding artery.
Animal Groups
Our institution’s Animal Care and Use Committee
approved the study, and all animal care and procedures
were performed under institutional guidelines. Our study
was carried out between March and August 2008. Fifteen
adult New Zealand white male rabbits weighing 3.8–
4.3 kg (Myrtle’s Rabbitry, Thompson Station, TN) were
used for this study. The rabbits were divided into three
groups of five rabbits each, based on selected time points
of euthanasia (1, 3, and 7 days after the treatment). Three
more rabbits were blandly embolized and used as
controls.
Anesthesia and Analgesia
As a premedication, a mixture of acepromazine (2.5 mg/kg;
Phoenix, St. Joseph, MO) and ketamine hydrochloride
(44 mg/kg; Phoenix, St. Joseph, MO) was injected intra-
muscularly. Intravenous access was secured via a marginal
ear vein, and 0.1–0.2 ml (2.5–5 mg) of sodium pentobar-
bital (Hospira, Inc., Lake Forest, IL) was administered
intravenously to maintain anesthesia. During each hepatic
artery intervention, all rabbits were intubated with a 3.0-mm
endotracheal tube (Mallinckrodt Medical, St. Louis, MO) to
measure end-tidal CO2 and respiration rate. After surgery,
analgesic buprenorphine (0.02–0.05 mg/kg) was injected
intramuscularly for pain relief.
Tumor Implantation
To obtain solid tumor for the implantation, 125 ll of a
Vx-2 carcinoma cell suspension was injected into each thigh
muscle of a carrier rabbit. One week later, distinct solid
tumors that had grown in each thigh muscle were harvested
from a carrier rabbit and put into 0.9% sodium chloride.
All rabbits were shaved in the thoracoabdominal area
before tumor implantation. The site of implantation was
identified using percutaneous ultrasonography (Aloka Co.,
Ltd., Tokyo; 7.5-MHz probe) via a low intercostal or
subcostal sonic window. Both the probe- and the ultra-
sound-inspected skin surface were sterile. A small (2- to
3-mm) skin incision was made with a scalpel at the decided
point for percutaneous puncture. The target site for
implantation was punctured by percutaneous ultrasound
guidance with a 16-G, 2-in.-long angiocath. After the
needle tip location was confirmed, the minced tumor cells
were inserted using a 0.035-in. guidewire.
Hepatic Artery Intervention
Three weeks after the tumor implantation, selective hepatic
arterial delivery of doxorubicin-loaded QSMs was per-
formed. Under intravenous anesthesia and intubation as
described above, intervention was performed with a digital
subtraction angiographic machine (Toshiba, Tokyo). Sur-
gical cutdown of the right-side femoral artery and insertion
of 4-Fr sheath (Cook, Inc., Bloomington, IN) were
% absorption ¼ initial drug concentration  drug concentration in the supernatant
initial drug concentration
 100
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performed to gain access into the abdominal aorta and
select hepatic artery. A 2-Fr JB1 catheter (Cook, Bloom-
ington, IN) was manipulated into the celiac trunk and
common hepatic artery. By performing a common hepatic
arteriogram, hepatic arterial anatomy, tumor staining and
vascularity, size, and location were verified. The JB1
catheter was first exchanged for a fiber-braided hydrophilic
2.5-Fr microcatheter (Renegade; Boston Scientific, Natick,
MA) over a 0.014–in. hydrophilic guidewire (Transend;
Boston Scientific/Medi-tech, Miami, FL), the tumor feed-
ing artery was then selected and the doxorubicin-loaded or
plain QSM solution was injected. After the procedure, the
common femoral artery was ligated using absorbable
suture material.
Plasma Concentration of Doxorubicin/Doxorubicinol
After each transcatheter arterial delivery of doxorubicin-
loaded QSMs, whole-blood samples (5 ml) were collected
to measure the plasma concentration of doxorubicin and
doxorubicinol at various time points (20, 40, 60, and
120 min). According to previous experience with testing
drug-loaded microspheres in the VX-2 rabbit model of
liver cancer, the plasma doxorubicin levels beyond
120 min were very low or beyond the level of detection,
and therefore, we decided that the end point for the phar-
macokinetic study would be the 120-min time point.
Whole-blood samples were placed on ice and centrifuged
within 3.5 h at 2000 rpm for 10 min at room temperature.
Fig. 3 In vitro doxorubicin
loading and release profiles of
QuadraSphere microspheres.
The three size ranges tested,
HS75, HS125, and HS180, have
a mean diameter of 90, 121, and
170 lm, respectively. A
Doxorubicin loadability profile.
B Doxorubicin release profile
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Isolated plasma was frozen at –20C refrigerator until the
time of analysis.
Tumor Doxorubicin Concentration and Histopathology
At each time point, rabbits were euthanized under deep
anesthesia by slow intravenous injection of a lethal dose
(100 mg/ml) of sodium pentobarbital. Samples from the
tumor, peritumoral liver parenchyma, and nontargeted liver
tissues in the left and right lobe were obtained. These tissue
samples were placed in a dry ice container immediately
after preparation and frozen at –80C until the time of
analysis. Doxorubicin concentration analysis was per-
formed via atomic absorption spectroscopy. Pieces from
the tumor core, tumor periphery, and peritumoral sur-
rounding liver parenchyma were stained with H&E and
sent for pathologic analysis. Tumor necrosis as seen with
H&E on pathology slides was estimated using a freeware
image analysis program (Image J; NIH, Bethesda, MD).
Results
The in vitro experiment showed 82–94% maximal doxo-
rubicin loadability into the QSMs at 2 h and 6% doxoru-
bicin release within the first 6 h, followed by a slow drug
release pattern (Fig. 3A, B).
All implanted Vx-2 tumors were grown successfully in
the liver, with a mean axial diameter of 3.0 cm (SD,
±0.3 cm), measured on pathology. A sufficient tumor size
and hypertrophic tumor feeding artery allowed the selec-
tive arteriography in all rabbits, and selective delivery of
the whole amount of doxorubicin-loaded QSM (5 mg
doxorubicin/1 ml) was possible.
In our study, the highest doxorubicin plasma concentra-
tion was noted at 20 min after treatment (mean: 0.1041 lM),
which subsequently dropped over time (Fig. 4A). Of note,
doxorubicin levels were not measured between 0 and 19 min
after injection, since the 20-min time point was our initial
one.
High intratumoral doxorubicin concentrations were
recorded during the first 3 days following treatment (mean
ranges, 40.632–50.052 nM/g) (Fig. 4B). At 7 days fol-
lowing treatment (the latest time point of our study),
intratumoral doxorubicin concentration dropped to 23.1372
nM/g. The percentage drug concentration in the peritu-
moral liver parenchyma ranged from 5.6% to 6.2% of the
intratumoral concentration. Doxorubicin concentrations in
the nontargeted left and right lobe of the liver were unde-
tectable (\0.6 nM/g).
Upon histopathology, an initial burst of tumor necrosis
was observed at 3 days and a pronounced 90% tumor
killing effect was achieved at 7 days after treatment with
doxorubicin-loaded QSMs. At 7 days, the control group
achieved 60% tumor necrosis (Fig. 5). Of note, the Vx-2
tumor model is notorious for being necrotic at baseline, and
according to our experience, a 40% tumor necrosis was
expected and taken into account when comparing groups
[3]. The intratumoral presence of doxorubicin-loaded
QSMs was well demonstrated in all rabbits (Fig. 6A, B).
Fig. 4 Pharmacokinetic profile of doxorubicin-loaded QuadraSphere
microspheres. A Doxorubicin and doxorubicinol plasma concentra-
tions over time. B Intratumoral and peritumoral tissue concentrations
of doxorubicin at selected time points of euthanasia
Fig. 5 Tumor cell death rates. At 7 days after treatment, a 90% mean
tumor necrosis rate was observed in the doxorubicin QSM group,
compared to a mean tumor necrosis of 60% seen in the control bland
embolization group
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Discussion
In this animal study, we utilized poly(vinyl alcohol-sodium
acrylate) copolymer microspheres (QSMs), which have the
unique feature of proportionally expanding in size when in
aqueous solution. Moreover, this material is a negatively
charged polymer and may interact with positively charged
drugs, such as doxorubicin. Our in vitro experiment dem-
onstrated a high doxorubicin loadability and sustained drug
release over time. Our in vivo study showed a safe phar-
macokinetic profile and sustained doxorubicin release over
time, with detectable intratumoral drug concentrations
and high tumoricidal effects at 7 days after treatment.
Moreover, the remarkable difference in doxorubicin con-
centration between intratumoral and peritumoral tissues
suggested that hepatic arterial delivery of doxorubicin-
loaded QSMs was done selectively. Histopathological
tumor necrosis at 7 days was more prominent in the group
treated with doxorubicin-loaded QSMs than in the bland
embolization group.
In our study, the highest doxorubicin plasma concen-
tration, which was noted at 20 min after treatment, was
0.1041 lM and subsequently dropped overtime. This value
is higher than the one measured at 20 min in the initial
rabbit study testing the efficacy of LC Beads [3]. This
difference could be attributed to the different biochemical
and physical properties of the two microspheres and sub-
sequent different drug loading and release patterns. In our
study, tumor necrosis at 7 days was high and comparable to
that observed at the same time point in the LC Beads study
(90% and 100%, respectively).
Our study has several limitations. We chose not to
directly compare our microspheres to the commercially
available drug-eluting beads, since we detected a stable
pharmacokinetic drug profile, with tumor killing compa-
rable to that reported in the rabbit LC Bead (Biocompati-
bles, Inc., UK) study performed by our group [2]. We also
chose not to include comparable numbers in a conventional
TACE control arm, since the superiority of doxorubicin-
loaded microspheres over chemoembolization was also
shown in the aforementioned study [2].
In summary, both in vitro and in vivo studies showed a
high drug loadability and sustained drug release over time,
high intratumoral doxorubicin concentrations at each time
point, and, on histopathology, increased tumor necrosis.
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